Immunogen (IMGN) Misses Q2 EPS by 2c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results
July 27, 2018 6:30 AM EDTMirvetuximab Soravtansine Granted Fast Track Designation by FDA
Encouraging Combination Data Reported from FORWARD II Expansion Cohort of Mirvetuximab with Avastin®; Initial Data from Expansion Cohort in Combination with Keytruda® to be Presented at ESMO
$163 Million Net Proceeds from Public Offering Extends Cash Runway
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS WIRE)--... More
